Sort   by:  
 Page size 
UnknownDurability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.
Not available
S-EPMC8078703 | biostudies-literature
UnknownSynthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals.
Not available
S-EPMC4351468 | biostudies-literature
UnknownImmune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis.
Not available
S-EPMC7158680 | biostudies-literature
UnknownAugmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.
Not available
S-EPMC5147865 | biostudies-literature
UnknownINO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.
Not available
S-EPMC8516974 | biostudies-literature
Unknown<i>In vivo</i> protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.
Not available
S-EPMC5707885 | biostudies-literature
UnknownA synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.
Not available
S-EPMC4573558 | biostudies-literature
UnknownSafety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
Not available
S-EPMC7759123 | biostudies-literature
Unknown571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Not available
S-EPMC8644048 | biostudies-literature
UnknownSARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
Not available
S-EPMC8807286 | biostudies-literature
Sort   by:  
 Page size